Inhaled Glucocoriticoids in Children: A Facourable Therapeutic Index

dc.contributor.author	Simons, F Estelle R
dc.date.accessioned	2016-06-09T14:55:47Z
dc.date.available	2016-06-09T14:55:47Z
dc.date.issued	1999-1-1
dc.date.updated	2016-06-07T07:02:15Z
dc.description.abstract	In children with persistent asthma, inhaled glucocorticoids decrease symptoms and exacerbations, decrease the need for rescue bronchodilator medications, improve airway patency and reduce airway hyperresponsiveness. When administered in the lowest doses that prevent symptoms and eliminate the need for supplemental courses of oral glucocorticoids, they are unlikely to cause clinically important systemic adverse events. Inhaled glucocorticoids have a favourable risk to benefit ratio in this population.
dc.description.version	Peer Reviewed
dc.identifier.citation	F Estelle R Simons, “Inhaled Glucocoriticoids in Children: A Facourable Therapeutic Index,” Canadian Respiratory Journal, vol. 6, no. 2, pp. 175-178, 1999. doi:10.1155/1999/957127
dc.identifier.uri	http://dx.doi.org/10.1155/1999/957127
dc.identifier.uri	http://hdl.handle.net/1993/31453
dc.language.rfc3066	en
dc.rights	open access	en_US
dc.rights.holder	Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.title	Inhaled Glucocoriticoids in Children: A Facourable Therapeutic Index
dc.type	Journal Article

Now showing 1 - 2 of 2

Now showing 1 - 1 of 1